影响尤因肉瘤中EWS-FLI1活性的因素
Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.
作者信息
Herrero-Martin David, Fourtouna Argyro, Niedan Stephan, Riedmann Lucia T, Schwentner Raphaela, Aryee Dave N T
机构信息
Children's Cancer Research Institute, St Anna Kinderkrebsforschung, 1090 Vienna, Austria.
出版信息
Sarcoma. 2011;2011:352580. doi: 10.1155/2011/352580. Epub 2011 Nov 10.
Abstract
Ewing's sarcoma family tumors (ESFT) are characterized by specific chromosomal translocations, which give rise to EWS-ETS chimeric proteins. These aberrant transcription factors are the main pathogenic drivers of ESFT. Elucidation of the factors influencing EWS-ETS expression and/or activity will guide the development of novel therapeutic agents against this fatal disease.
摘要
尤因肉瘤家族肿瘤（ESFT）的特征是特定的染色体易位，这会产生EWS-ETS嵌合蛋白。这些异常转录因子是ESFT的主要致病驱动因素。阐明影响EWS-ETS表达和/或活性的因素将指导针对这种致命疾病的新型治疗药物的开发。
相似文献
1
Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.
Sarcoma. 2011;2011:352580. doi: 10.1155/2011/352580. Epub 2011 Nov 10.
2
A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Dis Model Mech. 2012 Jan;5(1):95-106. doi: 10.1242/dmm.007401. Epub 2011 Oct 6.
3
A molecular function map of Ewing's sarcoma.
PLoS One. 2009;4(4):e5415. doi: 10.1371/journal.pone.0005415. Epub 2009 Apr 30.
4
Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue -- a report by the CWS-study group.
Klin Padiatr. 2004 Nov-Dec;216(6):315-22. doi: 10.1055/s-2004-832338.
5
Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Future Oncol. 2005 Aug;1(4):521-8. doi: 10.2217/14796694.1.4.521.
6
EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin.
Oncogene. 2005 Apr 7;24(15):2512-24. doi: 10.1038/sj.onc.1208455.
7
Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.
Cancer Res. 2006 Oct 15;66(20):9862-9. doi: 10.1158/0008-5472.CAN-05-4042.
8
The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity.
Oncogene. 2008 Feb 7;27(7):985-96. doi: 10.1038/sj.onc.1210705. Epub 2007 Aug 13.
9
The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
Pathol Oncol Res. 2011 Sep;17(3):619-25. doi: 10.1007/s12253-010-9358-3. Epub 2011 Jan 26.
10
Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma.
Cancer Res. 1999 Apr 1;59(7):1428-32.
引用本文的文献
1
The Double Life of microRNAs in Bone Sarcomas: Oncogenic Drivers and Tumor Suppressors.
Int J Mol Sci. 2025 May 17;26(10):4814. doi: 10.3390/ijms26104814.
2
Oncomeric Profiles of microRNAs as New Therapeutic Targets for Treatment of Ewing's Sarcoma: A Composite Review.
Genes (Basel). 2023 Sep 23;14(10):1849. doi: 10.3390/genes14101849.
3
Ewing sarcoma from molecular biology to the clinic.
Front Cell Dev Biol. 2023 Sep 11;11:1248753. doi: 10.3389/fcell.2023.1248753. eCollection 2023.
4
Regulation of Metastasis in Ewing Sarcoma.
Cancers (Basel). 2022 Oct 7;14(19):4902. doi: 10.3390/cancers14194902.
5
Liquid-liquid phase separation in tumor biology.
Signal Transduct Target Ther. 2022 Jul 8;7(1):221. doi: 10.1038/s41392-022-01076-x.
6
EWSR1 rearrangement in papillary thyroid microcarcinoma is related to classic morphology and the presence of small-cell phenotype.
Bosn J Basic Med Sci. 2022 Feb 1;22(1):54-63. doi: 10.17305/bjbms.2021.6181.
7
YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells.
Oncogenesis. 2021 Jan 8;10(1):2. doi: 10.1038/s41389-020-00294-8.
8
Preliminary Study on β3-Adrenoreceptor as Predictor Marker of Relapse in Ewing Sarcoma Patients.
Biomedicines. 2020 Oct 13;8(10):413. doi: 10.3390/biomedicines8100413.
9
Intrinsic Disorder of the BAF Complex: Roles in Chromatin Remodeling and Disease Development.
Int J Mol Sci. 2019 Oct 23;20(21):5260. doi: 10.3390/ijms20215260.
10
Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities.
J Pathol. 2018 Apr;244(5):638-649. doi: 10.1002/path.5042. Epub 2018 Mar 6.
本文引用的文献
1
Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.
PLoS One. 2011;6(8):e23592. doi: 10.1371/journal.pone.0023592. Epub 2011 Aug 10.
2
BLCAP induces apoptosis in human Ewing's sarcoma cells.
Exp Biol Med (Maywood). 2011 Sep;236(9):1030-5. doi: 10.1258/ebm.2011.010315. Epub 2011 Aug 15.
3
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
Clin Cancer Res. 2011 Sep 15;17(18):6052-60. doi: 10.1158/1078-0432.CCR-10-2979. Epub 2011 Jul 12.
4
Development of microRNA-145 for therapeutic application in breast cancer.
J Control Release. 2011 Nov 7;155(3):427-34. doi: 10.1016/j.jconrel.2011.06.026. Epub 2011 Jun 24.
5
Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
J Natl Cancer Inst. 2011 Jun 22;103(12):962-78. doi: 10.1093/jnci/djr156. Epub 2011 Jun 8.
6
A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
Oncogene. 2011 Dec 8;30(49):4910-20. doi: 10.1038/onc.2011.197. Epub 2011 Jun 6.
7
Targeting hypoxia in cancer therapy.
Nat Rev Cancer. 2011 Jun;11(6):393-410. doi: 10.1038/nrc3064.
8
Differential hypoxic regulation of hypoxia-inducible factors 1alpha and 2alpha.
Mol Cancer Res. 2011 Jun;9(6):757-65. doi: 10.1158/1541-7786.MCR-11-0053. Epub 2011 May 13.
9
YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.
PLoS One. 2011 Apr 29;6(4):e19343. doi: 10.1371/journal.pone.0019343.
10
Modeling initiation of Ewing sarcoma in human neural crest cells.
PLoS One. 2011 Apr 29;6(4):e19305. doi: 10.1371/journal.pone.0019305.
Zotero 插件